BARNET, ENGLAND, July 17, 2026 /24-7PressRelease/ -- The oncology market is one of the most information-rich environments in commercial medicine. Clinical trial data, real-world evidence, epidemiology reports, competitive pipeline assessments, treatment guidelines, and payer decisions all feed into the analytical models shaping pharmaceutical strategy. The challenge facing most organisations is not a shortage of data. It is the capacity to distinguish what the data means from what it appears to mean.

Stelios Tzellos, PhD, is a pharmaceutical analytics and oncology strategy leader based in the United Kingdom who has spent his career building the case for what he describes as evidence-led strategy: the practice of grounding commercial oncology decisions in genuine scientific understanding of disease, mechanism, and patient population, rather than in data patterns alone.

With a foundation in Molecular Biology from Imperial College London and analytical roles spanning GlobalData, IQVIA, and AstraZeneca, Tzellos has developed and applied this principle across forecasting, competitive assessment, and commercial planning.

Understanding Evidence-Led Strategy

Evidence-led strategy, as Tzellos defines it, is not the same as data-driven strategy. Data-driven strategy begins with the information available and builds models from it. Evidence-led strategy begins with the underlying biology and asks what the data should reflect, given how the disease and the therapy actually work.

"Data tells you what happened," Tzellos says. "Evidence tells you why it happened and whether it will happen again. In oncology, the difference between those two questions is the difference between a forecast that holds and one that does not."

The distinction matters because oncology markets are shaped by biological events: drug mechanisms that create durable responses, patient populations defined by biomarker profiles, resistance patterns that emerge over treatment lines. Understanding these dynamics requires scientific fluency, not just analytical skill.

Moving Away from Data Without Depth

In many commercial planning environments, data is abundant but interpretation is thin. Large datasets can produce the appearance of insight without the substance of it, particularly when the analysts working with the data lack the scientific background to recognise what the patterns are actually reflecting.

"You can have access to every piece of real-world evidence available and still produce the wrong forecast if you do not understand the mechanism driving the numbers," Tzellos explains. "The data is only as useful as the thinking that surrounds it."

Tzellos believes oncology analytics benefits from a higher standard of scientific grounding than many other therapeutic areas, because the consequences of strategic errors in oncology, for patients and for organisations, are correspondingly significant.

Where the Principle Came From

The evidence-led approach Tzellos brings to commercial strategy has roots in his academic training. His doctoral research at Imperial College London examined the molecular mechanisms of Epstein-Barr virus gene regulation, with a focus on why one EBV strain demonstrates greater efficiency in transforming human B cells. This kind of mechanistic inquiry, asking why a biological system behaves as it does rather than only observing that it does, became the analytical baseline he carried into professional practice.

At GlobalData, he applied this thinking to oncology market research, producing epidemiology models and competitive analyses for Hodgkin's lymphoma, multiple myeloma, and leukaemia. In each case, the analytical challenge required not just an understanding of commercial dynamics but the clinical reasoning behind them.

"At GlobalData and then at IQVIA, I worked across a range of oncology indications where the commercial dynamics were directly driven by the science," Tzellos says. "Understanding the biology was not background context. It was the primary input."

Evidence-Led Strategy as Daily Practice

Within a large pharmaceutical company, evidence-led strategy requires active maintenance. Commercial planning cycles move quickly. Inherited assumptions accumulate. Tzellos describes the core practice as a consistent return to first principles: examining the biological and clinical basis for every major commercial assumption, and asking whether it still reflects the current state of the science.

"Evidence-led strategy is not a one-time exercise," he says. "It is something you practise regularly, because the science in oncology does not stand still. The forecast that was grounded in evidence last year may not be grounded in evidence today."

At AstraZeneca, his work has spanned business insights, analytics, and oncology marketing, with a consistent focus on connecting scientific understanding to commercial planning in support of global product strategy.

Systems, Discipline, and Consistency

Tzellos describes the application of evidence-led strategy as a matter of system and discipline as much as expertise. A single analyst with deep scientific knowledge can produce excellent individual analyses. An organisation that builds scientific rigour into its commercial planning process, through structured approaches to assumption-testing and cross-functional dialogue between clinical and analytical teams, produces more reliable outputs over time.

"The molecule and the market are not separate questions," Tzellos says. "Organisations that treat them as separate end up with commercial strategies that are internally consistent but externally fragile. When the science moves, the plan breaks."

The structural response, in his view, is to create planning environments where scientific and commercial understanding are integrated from the beginning, not connected at the end of the process.

A Life Grounded in Consistent Effort

Outside of work, Tzellos pursues interests that mirror the values he brings to his professional approach. He follows football and basketball, sports defined by teamwork, discipline, and the compounding effect of consistent practice over time. His interest in DIY projects reflects a preference for hands-on problem-solving and the satisfaction of working through a challenge methodically. He attends concerts and the theatre regularly, and follows Formula 1, a competition in which analytical preparation and in-the-moment strategy together determine outcomes.

"The things I do outside of work remind me that attention to detail and consistent effort are not special practices," he says. "They are the standard approach for anyone who wants to produce reliable results."

He lives in the United Kingdom with his wife and their young family.

Looking Ahead

As oncology continues to generate new data sources and new analytical demands, Tzellos believes evidence-led strategy will become a differentiating capability rather than a standard expectation. The organisations that develop it now will be better positioned to manage the complexity of a landscape that shows no sign of becoming simpler.

"The molecule and the market are not separate questions," Tzellos concludes. "The more data we produce, the more important it becomes to understand what it means, and that understanding starts with the science."

# # #